Skip to main content

Table 4 Multivariable analysis of prognostic factors for the entire cohort

From: Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure

End point

Variable

HR

95%CI

P-value

OS

Sex(Male vs. Female)

0.722

0.592–0.882

0.001

WHO Histology (I ~ II vs. III)

0.643

0.443–0.935

0.021

Age, year (××45 vs. ≤45)

1.400

1.193–1.642

< 0.001

 N stage a ( N2-3 vs. N0-1)

1.417

1.199–1.674

< 0.001

Overall stage a ( IVa vs. III)

1.694

1.430–2.007

< 0.001

EBV DNA load, copy/ml (≥ 4000 vs. <4000)

1.462

1.228–1.741

< 0.001

CCD, mg/m 2

   

0

Reference

  

1-200

0.728

0.609–0.872

0.001

> 200

0.415

0.263–0.6550

< 0.001

DFS

Sex(Male vs. Female)

0.713

0.605–0.840

< 0.001

WHO Histology (I ~ II vs. III)

0.627

0.454–0.865

0.004

Age, year (××45vs. ≤45)

1.195

1.046–1.363

0.008

 N stage a ( N2-3 vs. N0-1)

1.297

1.131–1.488

< 0.001

Overall stage a ( IVa vs. III)

1.535

1.336–1.765

< 0.001

EBV DNA, copy/ml (≥ 4000 vs. <4000)

1.387

1.203–1.599

< 0.001

CCD, mg/m 2

   

0

Reference

  

1-200

0.778

0.668–0.906

0.001

> 200

0.531

0.376–0.750

< 0.001

LRFFS

WHO Histology (I ~ II vs. III)

0.610

0.380–0.979

0.040

 

Overall stage a ( IVa vs. III)

1.449

1.185–1.773

< 0.001

ELRRFS

WHO Histology (I ~ II vs. III)

0.354

0.144–0.874

0.024

LLRRFS

Age, year (××45 vs. ≤45)

1.324

1.063–1.649

0.012

Overall stage a ( IVa vs. III)

1.427

1.138–1.790

0.002

DMFS

N stage a (N0-1 vs.N2-3)

4.037

2.207–7.383

< 0.001

EDMFS

Sex(Male vs. Female)

0.674

0.497–0.913

0.011

 N stage a ( N2-3 vs. N0-1)

2.160

1.646–2.833

< 0.001

Overall stage a ( IVa vs. III)

1.376

1.070–1.770

0.013

EBV DNA, copy/ml (≥ 4000 vs. <4000)

2.152

1.615–2.867

< 0.001

CCD, mg/m 2

   

0

Reference

  

1-200

0.763

0.581–1.002

0.052

> 200

0.351

0.169–0.732

0.005

LDMFS

Sex(Male vs. Female)

0.667

0.480–0.926

0.016

WHO Histology (I ~ II vs. III)

0.481

0.275–0.843

0.011

 N stage a ( N2-3 vs. N0-1)

1.549

1.184–2.025

0.001

Overall stage a ( IVa vs. III)

1.608

1.230–2.102

0.001

  1. A Cox proportional hazards regression model was used to detect variables individually without adjustment. All variables were transformed into categorical variables. HRs were calculated for sex, WHO Histology, age, Family history, T stage, N stage, clinical stage, EBV-DNA before treatment, IC cycle, CCD
  2. Abbreviations: HR Hazard ratio, CI Confidence interval, OS Overall survival, DFS Disease- free survival, ELRFFS Early locoregional failure- free survival, LLRFFS Late locoregional failure- free survival, EDFFS Early distant failure-free survival, LDFFS Late distant failure-free survival, WHO World Health Organization, EBV Epstein–Barr virus, CCD Cumulative cisplatin dose
  3. aAccording to the 8th edition of the American Joint Commission on Cancer staging system
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us